Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
post-dose — exceeding the company's ~5–15% transduction target and including positive results in Class I ("null") mutation patients. Krystal plans to move rapidly into repeat-dosing (CORAL-3) and registrational discussions with the FDA and CFF, aiming to evaluate functional benefit by spirometry (FEV1) and to initiate a potential registrational study in the first half of the year. KB407 showed a favorable safety and immunogenicity profile — mostly mild-to-moderate transient adverse events, one bronchoscopy-related SAE, no significant neutralizing antibody response, and apparent lung-localized delivery — supporting feasibility of long-term repeat dosing. Interested in Krystal Biotech, Inc.? Here are five stocks we like better. Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) gene therapy candidate KB407, including molecular confirmation of wil
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]Seeking Alpha
- Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 8-K
- 12/23/25 - Form 8-K
- KRYS's page on the SEC website